Dermata Therapeutics (DRMA) Stock Overview
A late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
DRMA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Dermata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.86 |
| 52 Week High | US$23.70 |
| 52 Week Low | US$1.58 |
| Beta | 0.53 |
| 1 Month Change | -40.76% |
| 3 Month Change | -63.74% |
| 1 Year Change | -86.22% |
| 3 Year Change | -99.75% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| DRMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | -0.7% | -0.2% |
| 1Y | -86.2% | 26.8% | 17.1% |
Return vs Industry: DRMA underperformed the US Biotechs industry which returned 28% over the past year.
Return vs Market: DRMA underperformed the US Market which returned 17% over the past year.
Price Volatility
| DRMA volatility | |
|---|---|
| DRMA Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DRMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRMA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 8 | Gerry Proehl | www.dermatarx.com |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions.
Dermata Therapeutics, Inc. Fundamentals Summary
| DRMA fundamental statistics | |
|---|---|
| Market cap | US$1.91m |
| Earnings (TTM) | -US$8.85m |
| Revenue (TTM) | n/a |
Is DRMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRMA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.85m |
| Earnings | -US$8.85m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DRMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 18:48 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dermata Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Vendetti | Maxim Group |